Lauren C Harshman

Lauren C Harshman

UNVERIFIED PROFILE

Are you Lauren C Harshman?   Register this Author

Register author
Lauren C Harshman

Lauren C Harshman

Publications by authors named "Lauren C Harshman"

Are you Lauren C Harshman?   Register this Author

80Publications

1830Reads

29Profile Views

Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Curr Treat Options Oncol 2019 May 3;20(5):44. Epub 2019 May 3.

Lank Center for Genitourinary Cancers, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave (DANA 1230), Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-019-0639-0
Publisher Site
http://dx.doi.org/10.1007/s11864-019-0639-0DOI Listing
May 2019

Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy.

Urol Oncol 2018 09;36(9):400.e15-400.e22

Division of Urology and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.06.005DOI Listing
September 2018

Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.

Cancer 2018 03 19;124(5):925-933. Epub 2017 Dec 19.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31154DOI Listing
March 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.

Eur Urol 2017 10 12;72(4):483-487. Epub 2017 Apr 12.

Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.03.038DOI Listing
October 2017

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

J Immunother Cancer 2017 08 15;5(1):66. Epub 2017 Aug 15.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave D1230, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://jitc.biomedcentral.com/articles/10.1186/s40425-017-02
Publisher Site
http://dx.doi.org/10.1186/s40425-017-0273-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557522PMC
August 2017

Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy.

Clin Genitourin Cancer 2017 06 13;15(3):396-402. Epub 2016 Dec 13.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.12.009DOI Listing
June 2017

Too Much or Just Enough of a Good Thing: Vascular Endothelial Growth Factor Inhibition in Renal Cell Carcinoma?

J Clin Oncol 2017 06 13;35(16):1755-1757. Epub 2017 Mar 13.

Lauren C. Harshman, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8007DOI Listing
June 2017

Risk Assessment in Small Renal Masses: A Review Article.

Urol Clin North Am 2017 May;44(2):189-202

Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Boston, MA 02120, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2016.12.005DOI Listing
May 2017

Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management.

Curr Opin Urol 2016 11;26(6):548-55

aLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute bThe Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-urology/2016/11000/Programme
Web Search
http://dx.doi.org/10.1097/MOU.0000000000000332DOI Listing
November 2016

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clin Genitourin Cancer 2016 08 17;14(4):e299-305. Epub 2015 Dec 17.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.008DOI Listing
August 2016

Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?

Cancer 2016 07 25;122(13):1966-70. Epub 2016 May 25.

Lank Center for Genitourinary Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30027DOI Listing
July 2016

Diagnosis of Bladder Carcinoma: A Clinician's Perspective.

Surg Pathol Clin 2015 Dec;8(4):677-85

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2015.07.004DOI Listing
December 2015

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

JAMA Oncol 2015 Jul;1(4):495-504

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts2Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.0829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554437PMC
July 2015

Non-clear cell renal cell carcinoma, part 2: therapy.

Clin Adv Hematol Oncol 2015 Jun;13(6):383-91

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://annonc.oxfordjournals.org/content/early/2014/09/05/an
Web Search
June 2015

Non-clear cell renal cell carcinoma, part 1: histology.

Clin Adv Hematol Oncol 2015 May;13(5):308-13

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2015

Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.

Cancer J 2014 Jul-Aug;20(4):272-80

From the *Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA †Department of Oncology and the Brady Urological Institute, Johns Hopkins University, Baltimore, MD; and ‡Melanoma Disease Center and Center for Immuno-oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894310PMC
April 2015

Second-line therapies in metastatic urothelial carcinoma.

Hematol Oncol Clin North Am 2015 Apr 28;29(2):341-59, x. Epub 2015 Jan 28.

Department of Medicine, Stanford University School of Medicine, Blake Wilbur Drive, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.10.007DOI Listing
April 2015

Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma.

Clin Genitourin Cancer 2014 Dec 27;12(6):440-6. Epub 2014 Mar 27.

University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.03.009DOI Listing
December 2014

Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.

BioDrugs 2014 Dec;28(6):513-26

Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-014-0111-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888066PMC
December 2014

PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Cancer Immunol Res 2014 Dec;2(12):1132-41

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695990PMC
December 2014

Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Cancer Immunol Res 2014 Aug;2(8):714-9

Icahn School of Medicine at Mount Sinai, New York, New York

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0119DOI Listing
August 2014

Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.

Cancer J 2013 Jul-Aug;19(4):316-23

Dana-Farber Cancer Institute, Dana 1230 Solid Tumor Oncology, Lank Center for Genitourinary Oncology, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31829e3c9aDOI Listing
February 2014

Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.

Adv Ther 2013 Aug 27;30(8):727-47. Epub 2013 Aug 27.

Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-013-0050-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778906PMC
August 2013

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

Clin Genitourin Cancer 2013 Jun 24;11(2):100-6. Epub 2013 Jan 24.

Stanford Cancer Institute, Division of Oncology, Stanford School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2012.12.002DOI Listing
June 2013

Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).

Urol Oncol 2013 Apr 25;31(3):379-85. Epub 2011 Feb 25.

Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2011.01.005DOI Listing
April 2013

The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

JACC Heart Fail 2013 Feb 4;1(1):72-8. Epub 2013 Feb 4.

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchf.2012.09.001DOI Listing
February 2013

Cost-effectiveness analysis of nephron sparing options for the management of small renal masses.

J Urol 2011 May 21;185(5):1591-7. Epub 2011 Mar 21.

Division of Urology, and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2010.12.100DOI Listing
May 2011

The bevacizumab experience in advanced renal cell carcinoma.

Onco Targets Ther 2010 Oct 5;3:179-89. Epub 2010 Oct 5.

Division of Oncology, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962304PMC
October 2010

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

Chemotherapy 2009 27;55(5):321-6. Epub 2009 Jul 27.

Division of Oncology, Stanford University School of Medicine, Stanford, California 94305-1205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000230695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814022PMC
December 2009

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.

Cancer Invest 2009 Oct;27(8):851-6

Stanford University School of Medicine, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900902744528DOI Listing
October 2009

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Nat Rev Urol 2009 Jun;6(6):338-43

Division of Oncology, Stanford University Medical Center, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2009.84DOI Listing
June 2009

The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.

Am J Clin Oncol 2008 Oct;31(5):417-23

Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e318168ef47DOI Listing
October 2008

Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Expert Rev Anticancer Ther 2007 Dec;7(12):1749-61

Fellow, Medical Oncology, Stanford University School of Medicine, Division of Medical Oncology, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.7.12.1749DOI Listing
December 2007